Van ECK Associates Corp Has $237.67 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Van ECK Associates Corp lowered its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 44.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 723,471 shares of the medical research company’s stock after selling 580,281 shares during the period. Van ECK Associates Corp’s holdings in Bio-Rad Laboratories were worth $237,667,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. UMB Bank n.a. raised its position in Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Bio-Rad Laboratories during the third quarter worth about $32,000. Point72 Hong Kong Ltd acquired a new position in shares of Bio-Rad Laboratories in the third quarter worth approximately $55,000. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in Bio-Rad Laboratories by 281.7% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 271 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 200 shares during the last quarter. Finally, Quarry LP increased its position in Bio-Rad Laboratories by 38.1% during the 3rd quarter. Quarry LP now owns 297 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 82 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 0.8 %

NYSE BIO opened at $312.11 on Thursday. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The business has a 50 day moving average price of $340.05 and a 200-day moving average price of $336.74. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The company has a market cap of $8.74 billion, a price-to-earnings ratio of -11.42 and a beta of 0.90.

Wall Street Analysts Forecast Growth

BIO has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Citigroup increased their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.